Cellectis S.A.
Cellectis S.A. is a clinical-stage biotechnology company focused on gene-editing technologies for cell and gene therapies. It develops allogeneic CAR T-cell cancer therapies and gene-therapy programs through a platform that combines research, engineering, and in-house manufacturing, with operations centered in Paris and additional sites in New York and Raleigh.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaOff-the-shelf gene-edited CAR T-cell candidates designed for oncology treatment.
Gene-editing programs and platform work applied to non-oncology therapeutic indications.
Internal discovery, engineering, and translational development supporting pipeline creation.
In-house cell and gene therapy manufacturing capabilities supporting clinical programs.
Asiakkaat
Cellectis primarily serves patients through its drug-development pipeline rather than selling commercial products to end markets. Its direct counterparties are typically biopharma partners, research collaborators, clinical investigators, and regulators involved in advancing cell and gene therapy programs. In practice, value creation depends on successful clinical development, manufacturing execution, and eventual partnering or commercialization.
Patients and treatment centers involved in CAR T-cell trials for cancer indications.
Companies that license, co-develop, or collaborate on gene-edited therapy assets.
Academic and clinical organizations supporting preclinical and trial development.
Agencies and ethics bodies that approve or monitor clinical and manufacturing activity.
Strategia
Cellectis’ strategy centers on using gene editing to build off-the-shelf CAR T-cell therapies and a broader therapeutic platform. A key strategic differentiator is its end-to-end control of development and manufacturing, which can support product quality, process control, and translational speed across the value chain.
Clinical proof-of-concept is central to pipeline value in cell therapy.
Diversifies the platform beyond oncology and broadens commercial optionality.
Process consistency and supply reliability are critical in complex cell therapies.
Maantiede
Cellectis is headquartered in Paris, France, with operating locations in New York and Raleigh, North Carolina. The business is inherently international because research, clinical development, manufacturing, and investor access span Europe and the United States, and the company is listed in both the U.S. and France.
Riskit
Cellectis faces the binary development risk typical of clinical-stage biotechnology companies, where trial outcomes, safety signals, and regulatory decisions can determine program value. It also has meaningful legal and intellectual-property exposure, along with manufacturing complexity and dependence on successful scale-up of advanced therapies.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
Pipeline value depends on demonstrating safety and efficacy in human trials.
Kohdistuu: CAR T and gene therapy programs
- Intellectual property disputesVaikutus: KorkeaTodennäköisyys: Kohtalainen
The business relies on licensed and proprietary gene-editing rights.
Kohdistuu: Patent licenses and therapeutic editing platforms
- Manufacturing and scale-up riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Cell therapies require tightly controlled production and release processes.
Kohdistuu: In-house manufacturing and clinical supply
- Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Advanced therapies require extensive review before and during trials.
Kohdistuu: Clinical and manufacturing approvals
Kirjanpito
Harkinnanvaraiset erätMost pipeline costs are expensed as incurred, shaping reported losses and period comparability.
Vaikutus: High ongoing operating expense sensitivity
Non-cash equity awards are material enough that management presents an adjusted metric excluding them.
Vaikutus: Affects adjusted versus IFRS earnings comparison
Disputes or termination claims can create legal exposure and accounting judgments.
Vaikutus: Possible contingent liabilities or disclosure obligations
New statement classification and management-defined performance measures may affect comparability.
Vaikutus: Potential changes in presentation and subtotal disclosure
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics, Inc.
ALLO · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease.
Legend Biotech Corp
LEGN · Pharmaceutical Preparations
Legend Biotech Corp is a cell therapy company focused on discovering, developing, manufacturing, and commercializing novel treatments for cancer and other serious diseases.
Celularity Inc
CELU · Pharmaceutical Preparations
Celcuity Inc.
CELC · Services-Medical Laboratories
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
Päivitetty: 28.9.2026